📋 Browse Articles

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
Filtered by: CLN3 ✕ clear all
🏷️ Tags (31969 usages)
📦 Other 1510
▸ Other (850)
brain-derived neurotrophic factor (39)neuroplasticity (32)exercise (20)neurobiology (19)neurotoxicity (18)trkb (16)traditional chinese medicine (15)genetics (15)neurotrophic factors (14)hippocampal (13)central nervous system (12)neuroprotective (11)gut-brain axis (10)neurology (10)stroke (10)obesity (9)neurotrophic (9)psychology (9)dementia (9)zebrafish (8)bipolar disorder (8)neurotrophins (8)blood-brain barrier (8)aging (7)anti-inflammatory (7)neuropsychiatric disorders (7)memory (7)nanoparticles (7)neuropathic pain (7)neurotransmission (6)neurological disorders (6)mental health (6)neurotrophin (6)rats (6)stem cells (6)neuromodulation (6)astrocytes (6)neurodevelopmental disorders (6)psychiatry (6)cns (5)neuronal cells (5)meta-analysis (5)bioavailability (5)biochemistry (5)pathology (5)psychedelics (5)probiotics (5)amyloid-β (5)epilepsy (5)neurodevelopment (5)polymorphism (5)akt (5)aerobic exercise (5)astrocyte (4)nutrition (4)metabolomics (4)toxicity (4)neuroimmune (4)amyloid beta (4)myokines (4)brain health (4)rat model (4)physical exercise (4)neurotransmitter (4)ischemic stroke (4)neuropathology (4)physical activity (4)ngf (4)mesenchymal stem cells (4)neurodevelopmental disorder (4)physiological (3)overactive bladder (3)neuroblastoma (3)amyloid-beta (3)pathophysiology (3)extracellular vesicles (3)immune cells (3)microbiota (3)pi3k (3)neurotransmitters (3)pain management (3)camp (3)il-6 (3)neuronal survival (3)erk (3)hypoxia (3)interleukin-6 (3)estrogen (3)amyloid (3)neural development (3)intervention (3)neurobehavioral (3)voiding dysfunction (3)bioinformatics (3)metabolic (3)immunomodulation (3)ischemia (3)mitophagy (3)long-term potentiation (3)extracellular matrix (3)chemotherapy (3)brain function (3)psilocybin (3)microbiome (3)neuroendocrine (3)endocrine (3)cytokines (3)mouse model (3)neuropsychiatric (3)gastrointestinal (3)psychiatric disorders (3)sciatic nerve injury (3)anxiety disorders (3)hyperlipidemia (3)neurobiological (3)nerve growth factor (2)neuronal function (2)developmental toxicity (2)neural (2)gut health (2)biological (2)immunology (2)camkii (2)excitotoxicity (2)electrophysiological (2)urinary biomarkers (2)val66met polymorphism (2)behavioral (2)neuronal development (2)sleep deprivation (2)alpha-synuclein (2)neurological deficits (2)neuropsychiatry (2)empagliflozin (2)p2x4r (2)psychiatric disorder (2)cytokine (2)physiology (2)polyphenol (2)western diet (2)amnesia (2)calcium (2)multi-omics (2)gene therapy (2)neural stem cells (2)magnetic stimulation (2)exercise interventions (2)generalized anxiety disorder (2)serotonergic (2)yoga (2)microglial polarization (2)ischemic brain injury (2)mdd (2)in vivo (2)suicide (2)pathogenesis (2)anesthesia (2)cell death (2)substance use disorders (2)skeletal muscle (2)lead (2)radiotherapy (2)cardiology (2)5-ht (2)lactate (2)lipopolysaccharide (2)inflammatory (2)intermittent fasting (2)brain-gut axis (2)microgravity (2)mindfulness (2)hippocampal bdnf (2)hypertension (2)immunomodulatory (2)flavonoid (2)bone marrow (2)polyunsaturated fatty acids (2)ganoderma lucidum (2)pain (2)high-fat diet (2)gsk-3β (2)tissue engineering (2)adhd (2)il-10 (2)ampk (2)pink1 (2)microglial activation (2)muscle atrophy (2)amplitude (2)peripheral neuropathy (2)tissue plasminogen activator (2)metabolic health (2)healthy aging (2)wild (1)protein kinase (1)pesticide (1)brain abnormalities (1)immune (1)neural health (1)apoe (1)plant-based (1)cellular models (1)neurodevelopmental trajectories (1)synthesis (1)neurobehavioral toxicity (1)cas9 (1)histology (1)electrical stimulation (1)microglial dysfunction (1)hippocampal neurogenesis (1)plasticity (1)glutamatergic (1)phytochemical (1)urinary ngf (1)muscle weakness (1)gα (1)probdnf (1)stem cell therapy (1)nogo-a (1)schwann cell (1)diabetic neuropathy (1)blood biomarker (1)memantine (1)gs3kβ pathway (1)akt1 (1)nssi (1)ect (1)matrix metalloproteinases (1)nme3 (1)biology (1)platelet activation (1)whole-body vibration (1)gestation (1)neuronal plasticity (1)brain barriers (1)neurotransmitter systems (1)biomedicine (1)excipient selection (1)misa (1)genetic polymorphism (1)gsк-3β (1)bayesian network meta-analysis (1)addictive behaviors (1)motor neurons (1)chemical (1)tlr4 (1)psychotherapy (1)plga (1)atrazine (1)induced pluripotent stem cells (1)processed products (1)mental illness (1)nr2b (1)dendritic atrophy (1)domestication (1)adverse childhood experiences (1)hydrophobic interior (1)gestational intermittent hypoxia (1)neuropathy (1)calcineurin (1)sepsis-associated brain injury (1)gdnf (1)crispr (1)becn1 (1)appetite (1)derivatives (1)pediatric (1)nanocage (1)fibromyalgia (1)omega-3 fatty acids (1)paroxetine (1)mri (1)methyl donor (1)neuromodulatory (1)embryo development (1)case management (1)brain aging (1)bcl-2 (1)mettl3 (1)htr2c (1)psychological disorders (1)neurite outgrowth (1)erythropoietin (1)mastication (1)proteolytic processing (1)brain distribution (1)methylation (1)mental disorder (1)intestinal flora (1)pet (1)histone deacetylase (1)gut microbiome (1)proteome (1)klotho (1)attention deficit hyperactivity disorder (1)synthetic cannabinoid (1)human health (1)gene (1)metaplasticity (1)pkb (1)neurotherapeutics (1)sciatic nerve ligation (1)play behaviour (1)pediatric motor disorder (1)eeg (1)mood (1)cxcr4 (1)de novo lipogenesis (1)ultrasound (1)psychiatric therapies (1)nf-kappa b (1)excitatory synapses (1)hap1 (1)therapy (1)il6 (1)neat1 (1)pppar (1)surgical management (1)biochemical role (1)interleukins (1)agrochemical (1)calcium channels (1)neuronal activation (1)protein (1)pathophenotypes (1)glycation (1)dyspnea (1)genomics (1)epidemiology (1)acetylcholinesterase (1)polymorphic variants (1)thiazole (1)perinatal programming (1)neural pathways (1)degradation (1)uveitis (1)synthetic opioid (1)nanocarriers (1)vitamin d3 (1)metabolic dysfunction (1)astroglia (1)pparα (1)pfas (1)glial cells (1)ace2 (1)muscle (1)network (1)uhplc-q-tof-ms/ms (1)sglt2 inhibitor (1)biological aging (1)biochemical analysis (1)astrobiology (1)microbiota-gut-brain axis (1)local translation (1)wharton's jelly (1)essential oil (1)upper motor neuron (1)vulnerability (1)visceral pain (1)adolescence (1)histological damage (1)amyk (1)systemic (1)neural alterations (1)maoa (1)neuroprotectants (1)metabolic flexibility (1)polycystic ovary syndrome (1)neuroprotectors (1)trk (1)genotype (1)migration (1)brain metastases (1)jak2 (1)neuron-microglia interactions (1)behavioral disorders (1)hsd10 (1)aging brain (1)neurotoxicants (1)cell biology (1)neurological function (1)pkr inhibition (1)mict (1)antipsychotic (1)child mental disorder (1)blood brain barrier (1)stat3 (1)ipsc-derived neurons (1)cannabis (1)sepsis-associated encephalopathy (1)functional (1)olfaction (1)protein design (1)neurons (1)genetic background (1)axon growth (1)metformin (1)atf4 (1)blood-based biomarkers (1)multisystem (1)neutrophil extracellular traps (1)cd4 (1)phenolic acid (1)tissue inhibitors of metalloproteinases (1)inflammasome (1)obstetrics (1)fat oxidation (1)ondansetron (1)physical function (1)ipsc (1)ythdf1 (1)glymphatic function (1)immune system (1)nutritional strategies (1)anesthetics (1)ich (1)electroencephalogram (1)rodent models (1)in vivo study (1)phthalates (1)physiotherapy (1)nlrp3 (1)electroporation (1)older adults (1)sexual dysfunction (1)mice (1)sesquiterpenoid (1)fibrinolytic (1)gut-brain interactions (1)n-acetylcysteine (1)body weight (1)mfn2 (1)rat brain (1)hiit (1)inflammatory process (1)spinal disc (1)pacap (1)opioid use (1)ayahuasca (1)genetic risk factor (1)pkc delta (1)endothelial cells (1)lactation (1)hepatocellular carcinoma (1)cell viability (1)necrotic cell death (1)offspring behavior (1)cholinergic dysfunction (1)neurobiomarkers (1)neurotrophin-3 (1)canagliflozin (1)anxiety disorder (1)orthopedic fixation (1)neurodevelopmental biology (1)fragile x syndrome (1)npas4 (1)mesoporous silica (1)cardioprotective (1)hydrocephalus (1)neurological disorder (1)microbiomics (1)nanotherapeutics (1)tubulin (1)neuroinflammatory signalling (1)sineup (1)p75ntr (1)8-iso-pgf2α (1)diabetic neuropathic pain (1)lumbrokinase (1)nlrp3 inflammasome (1)neural organoid (1)neurobiochemistry (1)photoplethysmography (1)cadmium (1)fibroblast-growth factor-21 (1)bulimia (1)calcium-binding protein (1)nursing intervention (1)lipid rafts (1)hallucinogens (1)immune checkpoint (1)trka (1)biological markers (1)social interaction (1)systemic inflammation (1)passive smoking (1)atp production (1)nad (1)biological pathways (1)endocrine disorder (1)decline (1)anxiolytic (1)translation (1)kinases (1)personalized medicine (1)protein formulation (1)vagus nerve (1)carbon dots (1)aerobic (1)in vivo efficacy (1)polyphenols (1)motivational behaviors (1)gonadal hormones (1)nanotechnology (1)neurological growth (1)mitogen-activated protein kinase (1)cannabidiol (1)neuronal degeneration (1)oxidative damage (1)public health (1)radiation-induced brain injury (1)cholinergic (1)therapeutics (1)meditation (1)salmon (1)gut brain axis (1)chemokines (1)toxoplasma gondii (1)omics (1)bdnf/trkb pathway (1)neuroanatomy (1)hepatoprotective (1)nanofibers (1)growth factor (1)dietary triglyceride (1)eating behavior (1)tgf-β (1)homing (1)neuropsychology (1)visual stimulation (1)histone (1)t cells (1)diabetic ischemic brain injury (1)bax (1)behavioral performance (1)prkn (1)metabolic alterations (1)stem cell (1)axon guidance (1)sumoylation (1)acd (1)erbb4 inhibitor (1)two-hit model (1)perk (1)tug1 (1)gene activation (1)tea polyphenols (1)tcm (1)developmental neurotoxicity (1)hormonal (1)plasmin (1)emotion axis (1)bdnf pathway (1)mmp-9 (1)heavy metal (1)histologic analysis (1)platelet factor 4 (1)fisetin (1)neurobehavioral deficits (1)anaerobic exercise (1)hypoxanthine (1)motor function (1)hippocampal neurons (1)psychedelic (1)nutritional psychiatry (1)nerve injury (1)brain-derived neurotrophic factors (1)behaviors (1)mct oil (1)hippocampal plasticity (1)hippocampal development (1)kcc2 (1)peripheral blood mononuclear cells (1)ecb (1)pcl (1)exercise intervention (1)glial scarring (1)ovine (1)lung-brain axis (1)hyperventilation syndrome (1)hbv (1)endocannabinoid pathways (1)geriatrics (1)neonatal brain proteomics (1)muscle pain (1)etiology (1)weightlessness (1)biodegradable materials (1)ho-1 (1)pain subtypes (1)cxcl12 (1)bdnf signalling (1)p2x7r (1)salivary gland (1)cholesterol (1)vitamin d (1)behavior (1)nmda (1)genetic (1)sociodemographic factors (1)neuroprotective properties (1)ethanol (1)oral delivery (1)suicidal ideation (1)neurophysiology (1)synovial fibroblasts (1)translational (1)bioactivity (1)function (1)neural stimulation (1)muscle function (1)ophthalmology (1)gene-tbi interactions (1)macrophages (1)cannabinoid (1)fatty acids (1)piezoelectric (1)tms (1)hepatic encephalopathy (1)mood disorders (1)tph2 (1)cardiometabolic disease (1)psychological (1)single-nucleotide variants (1)schwann cells (1)euglena gracilis (1)inflammatory bowel disease (1)intestinal barrier (1)emotional disorders (1)hyperammonemia (1)5-ht pathway (1)app (1)sleep (1)olfactory system (1)neurovegetative (1)beta-glucan (1)lithium chloride (1)psychobiotics (1)brainstem (1)neuronal growth (1)glioma (1)apolipoprotein e (1)psychotropic (1)substance use disorder (1)neurobiological alterations (1)dendritic morphology (1)b-cell lymphoma 2 (1)puberty (1)cmd (1)electromagnetic field (1)neurochemicals (1)pgc1α (1)low back pain (1)dheas (1)biological sciences (1)intranasal delivery (1)neurotrophic hypothesis (1)cbt (1)sik1 (1)magnetically targeted (1)motor neuron disease (1)visceral hypersensitivity (1)psychiatric genetics (1)drp1 (1)butyrate (1)six3 (1)triclocarban (1)proteomic clustering (1)pharmaceutical (1)cellular nerve damage (1)parkin (1)sciatic nerve (1)pediatrics (1)sepsis (1)pcr (1)traditional uyghur medicine (1)murine model (1)bace1 (1)liquid crystalline (1)gwas (1)neuroblastoma cells (1)signalling pathway (1)brain oxygenation (1)paxillin (1)inflammatory markers (1)neural damage (1)mass spectrometry (1)sleep-promoting (1)monocytes (1)mh (1)sex hormones (1)brain biomarkers (1)immune activation (1)glutamatergic system (1)akt pathway (1)pituitary gland (1)neurochemistry (1)phytochemical analysis (1)plant (1)behavioral deficits (1)tnfα (1)psychiatric (1)peripheral nerve injury (1)clearance system (1)acrylamide (1)behavioral dysfunction (1)gut-hippocampus axis (1)neonatal development (1)vitamin c (1)ppparα (1)uflc-q-tof-ms/ms (1)stagnant phlegm syndrome (1)neurodelivery (1)cav1 (1)metabolic processes (1)gpr40 (1)na/k-atpase (1)nuclear translocation (1)nanoemulsion (1)pericytes (1)p2y1r (1)next-generation sequencing (1)neuroactive lignan (1)food intake (1)neuronal injury (1)muscle denervation (1)inflammatory pathways (1)sox5 (1)herbicide (1)neuroma (1)maya-mestizo population (1)dexras1 (1)msc (1)microcystin (1)amyloid plaque (1)cardiometabolic (1)rat models (1)val66met (1)rock1 (1)plasma technology (1)statins (1)bdnf-trkb pathway (1)mendelian randomization (1)protein kinase b (1)neural plasticity (1)oxidative balance (1)spleen-kidney deficiency (1)prisma (1)metabolic function (1)proinflammatory cytokines (1)antioxidative (1)multiple system atrophy (1)neurobehavior (1)mcao (1)herbal medicine (1)eating disorders (1)brain plasticity (1)hyperglycemia (1)visual function (1)peripheral brain-derived neurotrophic factor (1)lithium (1)dry eye model (1)hepatocyte (1)tnf-α (1)proteases (1)neurological health (1)steroid hormones (1)dendritic spine (1)uhplc-qtof-ms (1)social memory (1)perineuronal networks (1)phytoestrogen (1)childhood obesity (1)lc-ms (1)microvesicles (1)caspase-4 (1)inflammaging (1)muscle-brain axis (1)spions (1)therapeutic implications (1)adolescent brain (1)rotenone (1)metabolic syndrome (1)no (1)lineage (1)neural network (1)phq-9 (1)lipid-lowering (1)gene mutations (1)biochemical (1)pka (1)central sensitization (1)matrix metalloproteases (1)risperidone (1)morphological deficits (1)panax ginseng (1)bioprinted (1)neurotoxicity-associated metabolic alterations (1)polymorphisms (1)minocycline (1)ntrk (1)lcn2 (1)behavioral science (1)liver injury (1)pituitary (1)biophysics (1)cholinergic function (1)orthopedics (1)neural tissue (1)hippocampal injury (1)gastric ulcer (1)vitality (1)space medicine (1)igf-1 (1)intrinsic capacity (1)central nervous system disorders (1)neurodevelopmental studies (1)single-nucleotide polymorphisms (1)fasd (1)polygalae radix (1)exerkines (1)pathophysiological interactions (1)walking (1)chemobrain (1)neural function (1)ingestion (1)bangladeshi population (1)urodynamics (1)aβ plaques (1)immuno-modulation (1)pathway (1)neuroendocrinology (1)supplementation (1)brain tissue (1)cardiotoxicity (1)mglur5 (1)acetylation (1)microplastic (1)therapeutic perspectives (1)methylxanthine (1)naphthoquinone (1)myokine (1)analgesia (1)gst (1)choroid plexus (1)plasma biomarkers (1)glutamatergic pathways (1)biomaterials (1)global health (1)inhibitor (1)
⚗️ Metals 1041
▸ Metals — Other (620)
neuroscience (64)cognitive function (30)synaptic plasticity (25)stress (15)antidepressant (14)pharmacology (11)cognitive dysfunction (10)toxicology (9)cognition (9)serotonin (8)major depressive disorder (7)molecular biology (7)spinal cord injury (7)prefrontal cortex (7)chronic stress (6)autism spectrum disorder (6)chronic pain (6)exosomes (6)ptsd (6)cognitive (6)irisin (5)pregnancy (5)memory impairment (5)network pharmacology (5)cognitive performance (5)endoplasmic reticulum stress (5)neuropharmacology (5)environmental enrichment (4)homeostasis (4)oncology (4)neuroprotective effects (4)traumatic brain injury (4)molecular mechanisms (4)depressive disorder (4)cardiovascular (4)psychopharmacology (4)neuroregeneration (4)resveratrol (4)post-traumatic stress disorder (4)chitosan (4)affective disorders (3)osteoporosis (3)insomnia (3)high-intensity interval training (3)neurobiological mechanisms (3)serum (3)treatment-resistant depression (3)mirna (3)nerve regeneration (3)animal model (3)transcriptomics (3)acupuncture (3)sarcopenia (3)molecular dynamics (3)molecular (3)molecular docking (3)autism (3)rehabilitation (3)electroconvulsive therapy (3)regenerative medicine (3)bioactive compounds (3)prenatal stress (3)melatonin (3)cums (2)tau protein (2)cancer progression (2)er stress (2)glucocorticoid receptor (2)insulin resistance (2)preclinical (2)metabolic regulation (2)quality of life (2)docosahexaenoic acid (2)pharmacogenomics (2)neuroprotective mechanisms (2)gene regulation (2)heart failure (2)alcohol consumption (2)amyotrophic lateral sclerosis (2)ketogenic diet (2)neural circuitry (2)antidepressants (2)trauma (2)retina (2)neurovascular (2)mir-34a-5p (2)ginsenosides (2)stroke recovery (2)transcriptome (2)transcranial magnetic stimulation (2)systematic review (2)molecular pathways (2)regulatory mechanisms (2)executive function (2)postoperative care (2)neuroprotective effect (2)corticosterone (2)post-stroke depression (2)retinal ganglion cells (2)premature ejaculation (2)cognitive recovery (2)selenium (2)learning (2)pharmacological (2)glucagon-like peptide-1 (2)functional recovery (2)circadian rhythms (2)endocrine disruptors (2)early-life stress (2)axonal regeneration (2)naringenin (2)cognitive deficits (2)endoplasmic reticulum (2)alcohol (2)depressive behaviors (2)peripheral nerve regeneration (2)nmda receptor (2)cognitive health (2)cortisol (2)cytoskeleton (2)postoperative cognitive dysfunction (2)infralimbic cortex (2)cerebrum (2)cortical neurons (2)synaptic dysfunction (2)molecular targets (2)benzalkonium chloride (2)prebiotics (2)mild cognitive impairment (2)ethnopharmacology (2)cognitive functions (2)regeneration (2)tau (1)viral infections (1)stress responses (1)physicochemical characterization (1)brain immunity (1)correction (1)retinoic acid (1)post-translational modification (1)exposure (1)lucidenic acid a (1)hepatic steatosis (1)dietary regulation (1)nerve conduits (1)environmental pollutants (1)perigestational opioid exposure (1)meta-regression (1)mechanosensory hair cells (1)hippocampal ca2 region (1)neural precursors (1)photoreceptors (1)anaerobic glycolytic flux (1)respiratory (1)randomized controlled trials (1)ischemic postconditioning (1)molecular changes (1)growth cones (1)total abdominal irradiation (1)cardiovascular disease (1)aggression (1)gold nanoparticles (1)circrna (1)preclinical evidence (1)traumatic injury (1)dopamine d2 receptor (1)progressive (1)psychological trauma (1)drug metabolism (1)neural structure (1)synaptic transmission (1)laquinimod (1)preterm birth (1)resilience (1)peptide design (1)fermented food (1)spatial learning (1)complications (1)allergic contact dermatitis (1)particulate matter (1)corticospinal tract (1)chronic restraint stress (1)cerebellum (1)hepatitis b virus (1)copd (1)post-stroke cognitive impairment (1)tryptophan metabolism (1)ginsenoside (1)auricular vagus nerve stimulation (1)biosynthesis (1)scoping review (1)vascular endothelium (1)opioid prescription (1)mir-381-3p (1)learning-memory (1)fetal alcohol spectrum disorders (1)emotion perception (1)hippocampal structure (1)cell communication (1)sedative-hypnotic effects (1)amniotic fluid stem cell (1)cardiovascular disorders (1)nerve guidance conduits (1)regulatory network (1)synaptic impairment (1)peroxisome proliferator-activated receptor alpha (1)neurocognitive impairment (1)aquatic ecosystems (1)fibronectin type iii domain-containing protein 5 (1)phosphorylated tau (1)oxygen-glucose deprivation (1)chronicity (1)intracerebral hemorrhage (1)osteosarcopenia (1)behavioral responses (1)anorexia (1)selective serotonin reuptake inhibitors (1)stable love relationships (1)psychological treatment (1)hippocampal regeneration (1)redox homeostasis (1)neuroprotective molecules (1)neurovascular plasticity (1)neuropeptide (1)irradiation (1)hemorheological parameters (1)cellular mechanisms (1)cognitive flexibility (1)astrocytic disruption (1)alcohol dependence (1)stroke treatment (1)irritable bowel syndrome (1)seizure susceptibility (1)immune reactions (1)tumor necrosis factor alpha (1)mirnas (1)menopausal (1)microbiota dysbiosis (1)bed rest (1)nicotine (1)bone loss (1)cubosome formulation (1)post traumatic stress disorder (1)vascular dysfunction (1)hyperandrogenism (1)pd-1 (1)hippocampal neuronal apoptosis (1)prenatal exposure (1)pyroptosis (1)withaferin a (1)glycolysis (1)microenvironment (1)redox balance (1)circadian rhythm (1)olfactory exposure (1)nose-to-brain delivery (1)neurocognitive outcomes (1)sex differences (1)neuro-osteogenic microenvironment (1)acute ischemic stroke (1)psychedelic drugs (1)sinomenine (1)secretory protein (1)maladaptive neuroplasticity (1)facial recognition (1)stress disorder (1)carnosine (1)synaptic deficits (1)mir-146a-3p (1)regulation (1)ferritin (1)protein secretion (1)scopolamine-induced amnesia (1)randomized controlled trial (1)principal component analysis (1)appetite regulation (1)psychiatric comorbidities (1)environmental toxicology (1)gynecology (1)hif-1α-epo/camp-creb-bdnf pathway (1)depressive states (1)learning process (1)neural regeneration (1)cardiac arrest (1)psychological outcomes (1)affective states (1)gut dysbiosis (1)long non-coding rnas (1)prefrontal-limbic connectivity (1)psychological reaction (1)extremely low-frequency magnetic field (1)clinical assessment (1)microglial exosomes (1)neurotoxicology (1)epileptogenesis (1)clinical trial (1)anabolic-androgenic steroid (1)ethnic medicine (1)mitochondrial calcium uniporter (1)weight loss (1)amitriptyline (1)stress responsivity (1)serotonergic circuit (1)lps-induced depression (1)locomotion (1)steroidal saponin (1)aquatic organisms (1)correlation (1)drug response (1)transcriptomic (1)long non-coding rna (1)rheumatoid arthritis (1)rem theta (1)absorption (1)chronic heart failure (1)fentanyl administration (1)molecular toxicology (1)vascular cognitive impairment (1)motor impairment (1)adipose-derived stem cells (1)neuro-related disorders (1)emotional regulation (1)restraint stress (1)regenerative capabilities (1)antinociceptive (1)cerebral palsy (1)cerebral infarction (1)normal pressure hydrocephalus (1)positron emission tomography (1)bioengineered delivery system (1)adenosine (1)connexin43 (1)immunoregulation (1)comorbid (1)cerebrovascular disease (1)in silico (1)moderate-intensity continuous training (1)cognitive improvement (1)stress-induced depressive behaviors (1)drug delivery (1)lycopene delivery (1)host-virus interactions (1)phosphatidic acid (1)sirt1 (1)neuroserpin (1)heat stress (1)macular degeneration (1)medial prefrontal cortex (1)intranasal drug delivery (1)early diagnosis (1)rem sleep behavior disorder (1)seizures (1)psychosocial (1)prenatal supplementation (1)adeno-associated virus (1)neurotoxic effects (1)proanthocyanidins (1)neurocognitive (1)anti-inflammatory effects (1)gestational opioid exposure (1)nociceptive sensitization (1)stress axis regulation (1)anthocyanins (1)pruritus (1)phlorotannin (1)high intensity interval training (1)prosopis cineraria (1)psychosis (1)constipation (1)psychedelic compounds (1)delphinidin (1)myostatin (1)triterpenoid saponins (1)limbic structures (1)osteoblast (1)bdnf expression (1)poly(lactic-co-glycolic acid) (1)korean population (1)neuroimmune crosstalk (1)chronic diseases (1)low birthweight (1)α7 nicotinic acetylcholine receptor (1)protein quality control (1)peptide hydrogel (1)fecal calprotectin (1)metabolic adaptation (1)single-cell transcriptomics (1)cell differentiation (1)neurogenic bladder (1)hippocampal synaptic proteins (1)chemoresistance (1)herb pair (1)chronotropic incompetence (1)autism-like behavior (1)testicular health (1)aggressive behavior (1)allodynia (1)obstructive sleep apnea (1)opioid overdose (1)gold coast criteria (1)n-methyl-d-aspartate receptor (1)psychological stress (1)betulinic acid (1)retinal degeneration (1)depressive pathologies (1)traumatic event (1)ros (1)extremely low-frequency electromagnetic field (1)cognitive impairments (1)chronic toxoplasmosis (1)dacomitinib (1)serotonin 5-ht2a receptor (1)pulmonary fibrosis (1)psychostimulant (1)chronic unpredictable mild stress (1)tobacco smoke (1)radiofrequency electromagnetic fields (1)fetal brain development (1)sedative-hypnotic effect (1)social buffering (1)depressive disorders (1)epigenetic dysregulation (1)neuroimmune circuits (1)childhood growth restriction (1)resolvin d1 (1)molecular design (1)glp-1 receptor agonists (1)brain-gut homeostasis (1)neurotrophic adaptation (1)liver failure (1)creb pathway (1)diclofenac (1)n6-methyladenosine (1)immune mechanisms (1)laminin (1)cerebrovascular accidents (1)suicide attempt (1)neural repair (1)synaptic (1)adverse outcome pathway (1)opioid receptors (1)memory impairments (1)fibrotic remodeling (1)neuronal communication (1)appetite control (1)outcomes (1)hypothalamus-pituitary-adrenal axis (1)serum bdnf levels (1)lung homeostasis (1)perioperative neurocognitive disorders (1)cognitive training (1)melatonin receptor (1)adolescent social isolation stress (1)cognitive therapy (1)fear memory (1)osseointegration (1)musculoskeletal system (1)colitis (1)autoimmune uveitis (1)light treatment (1)cerebral protection (1)neurotrophic dysregulation (1)ingredient (1)developmental neurotoxicology (1)transcriptional changes (1)neurosteroids (1)environmental conditions (1)orthostatic hypotension (1)pathological microenvironment (1)autologous serum (1)physiological resilience (1)spatial transcriptomics (1)function recovery (1)age-related macular degeneration (1)seizure (1)mangiferin (1)preclinical models (1)herpes simplex virus (1)exosome-based therapy (1)peptides (1)melanocortin (1)tau phosphorylation (1)tumor necrosis factor (1)eicosapentaenoic acid (1)neural circuit (1)hypothalamic-pituitary-adrenal axis (1)brain structure (1)phosphatidylserine (1)irák1 (1)colorectal cancer (1)perinatal depression (1)learning ability (1)allostatic load (1)adolescent depression (1)creatine supplementation (1)affective dysfunction (1)non-pharmacological interventions (1)personal care products (1)diagnosis (1)unfolded protein response (1)antidepressant mechanisms (1)cerebral hemorrhage (1)autophagic pathway (1)nanocomposite hydrogel (1)causal relationship (1)fear extinction (1)neuropeptide s (1)nociceptive responses (1)dpd-4 inhibitors (1)traumatic stress disorder (1)colon cancer (1)tau hyperphosphorylation (1)tyrosine kinase receptor b (1)ecosystems (1)reproductive physiology (1)stress regulation (1)motor learning (1)disease-syndrome combined model (1)methionine-choline-deficient diet (1)s-nitrosylation (1)neurocognitive disorders (1)postmenopausal women (1)neural recovery (1)kaempferol (1)postoperative delirium (1)receptor (1)social cognition (1)neurocognition (1)environmental (1)hcortisolaemia (1)integrated stress response (1)systemic effects (1)antiretroviral therapy (1)adenosine receptor (1)late-life cognitive decline (1)traumatic memories (1)energy homeostasis (1)antidepressant effect (1)physiological adaptations (1)inflammatory responses (1)tissue architecture (1)vascularization (1)neuroimmune responses (1)human respiratory syncytial virus (1)vision loss (1)rapid antidepressant effects (1)tau pathology (1)drug release (1)signal peptide (1)noncommunicable diseases (1)electrospun (1)alcohol-induced cognitive impairment (1)vasoactive intestinal polypeptide (1)cognitive behavior (1)hypothalamic pituitary adrenal axis (1)machine learning (1)hypothalamic-pituitary adrenal axis (1)parkinsonism (1)cognitive resilience (1)impairment (1)experimental autoimmune uveoretinitis (1)precursor state (1)hmg-coa reductase inhibitors (1)tumor necrosis factor-α (1)relationship (1)cognitive aging (1)clinical psychology (1)antidepressant activity (1)optic nerve injury (1)mechanistic (1)vascular maturation (1)biomechanics (1)aerospace medicine (1)oncogenic drivers (1)differentiation (1)resistance training (1)paraventricular nucleus (1)ecotoxicity (1)synaptic homeostasis (1)environmental concern (1)bdnf/creb pathway (1)creb phosphorylation (1)mood dysregulation (1)nitrous oxide (1)dentate gyrus (1)paternal exposure (1)behavioral despair (1)nicotine exposure (1)lactobacillus plantarum (1)electroacupuncture (1)female mice (1)fetal neural development (1)tropomyosin receptor kinase b (1)environmental contaminants (1)differentiation protocols (1)magnetic resonance imaging (1)reward processing (1)arsenic (1)steroid effects (1)diosgenin (1)stress hormone (1)oral administration (1)hemorheology (1)synaptic models (1)reversal learning (1)synaptic signaling (1)cognitive outcomes (1)presynaptic (1)magnetic field exposure (1)ischemia reperfusion injury (1)nitric oxide (1)toxoplasmosis (1)tyrosine kinase inhibitors (1)acute hepatitis (1)glucagon-like peptide-1 receptor agonists (1)somatosensory cortex (1)serotonin pathway (1)biological effects (1)cyanidin (1)breast cancer (1)
💊 Drugs 4

🔍 Filters

936 articles with selected tags
W Kaczmarski, E Kida, A Lach +3 more · 1997 · Neuropediatrics · added 2026-04-24
Expression of the gene for Batten disease (CLN3) was studied in Escherichia coli and in a cell-free rabbit reticulocyte expression systems. A full-length recombinant fusion CLN3 protein was not produc Show more
Expression of the gene for Batten disease (CLN3) was studied in Escherichia coli and in a cell-free rabbit reticulocyte expression systems. A full-length recombinant fusion CLN3 protein was not produced in the bacterial systems used. However, both N-terminal fragment encompassing 246 amino acids and short C-terminal fragment containing 428-438 amino acids of the CLN3 protein were successfully overexpressed in bacteria. Further studies showed that the C-terminal sequence of the CLN3 protein corresponding to the 356-438 amino acid residues was responsible for inhibition of protein synthesis in bacteria. The full-length CLN3 gene product was readily synthesized in vitro in the cell-free rabbit reticulocyte expression system. The product obtained, corresponding to core CLN3 protein, showed an approximate molecular weight of 43 kDa. Immunoprecipitation of this product with pAb to 4-19 amino acids of the CLN3 protein allows us to suggest that CLN3 protein translation starts at Met-1. Show less
no PDF DOI: 10.1055/s-2007-973663
CLN3
M Polymenis, E V Schmidt · 1997 · Genes & development · Cold Spring Harbor Laboratory · added 2026-04-24
The eukaryotic cell cycle is driven by a cascade of cyclins and kinase partners including the G1 cyclin Cln3p in yeast. As the first step in this cascade, Cln3p is uniquely positioned to determine the Show more
The eukaryotic cell cycle is driven by a cascade of cyclins and kinase partners including the G1 cyclin Cln3p in yeast. As the first step in this cascade, Cln3p is uniquely positioned to determine the critical growth-rate threshold for division. To analyze factors regulating CLN3 expression, we identified a short upstream open reading frame (uORF) in the 5' leader of CLN3 mRNA as a translational control element. This control element is critical for the growth-dependent regulation of Cln3p synthesis because it specifically represses CLN3 expression during conditions of diminished protein synthesis or slow growth. Inactivation of the uORF accelerates the completion of Start and entry into the cell cycle suggesting that translational regulation of CLN3 provides a mechanism coupling cell growth and division. Show less
no PDF DOI: 10.1101/gad.11.19.2522
CLN3
M C Edwards, N Liegeois, J Horecka +4 more · 1997 · Genetics · Oxford University Press · added 2026-04-24
Regulated cell cycle progression depends on the proper integration of growth control pathways with the basic cell cycle machinery. While many of the central molecules such as cyclins, CDKs, and CKIs a Show more
Regulated cell cycle progression depends on the proper integration of growth control pathways with the basic cell cycle machinery. While many of the central molecules such as cyclins, CDKs, and CKIs are known, and many of the kinases and phosphatases that modify the CDKs have been identified, little is known about the additional layers of regulation that impinge upon these molecules. To identify new regulators of cell proliferation, we have selected for human and yeast cDNAs that when overexpressed were capable of specifically overcoming G1 arrest signals from the cell cycle branch of the mating pheromone pathway, while still maintaining the integrity of the transcriptional induction branch. We have identified 13 human CPR (cell cycle progression restoration) genes and 11 yeast OPY (overproduction-induced pheromone-resistant yeast) genes that specifically block the G1 arrest by mating pheromone. The CPR genes represent a variety of biochemical functions including a new cyclin, a tumor suppressor binding protein, chaperones, transcription factors, translation factors, RNA-binding proteins, as well as novel proteins. Several CPR genes require individual CLNs to promote pheromone resistance and those that require CLN3 increase the basal levels of Cln3 protein. Moreover, several of the yeast OPY genes have overlapping functions with the human CPR genes, indicating a possible conservation of roles. Show less
no PDF DOI: 10.1093/genetics/147.3.1063
CLN3
C Gallego, E Garí, N Colomina +2 more · 1997 · The EMBO journal · Oxford University Press · added 2026-04-24
Nutrients are among the most important trophic factors in all organisms. When deprived of essential nutrients, yeast cells use accumulated reserves to complete the current cycle and arrest in the foll Show more
Nutrients are among the most important trophic factors in all organisms. When deprived of essential nutrients, yeast cells use accumulated reserves to complete the current cycle and arrest in the following G1 phase. We show here that the Cln3 cyclin, which has a key role in the timely activation of SBF (Swi4-Swi6)- and MBF (Mbp1-Swi6)-dependent promoters in late G1, is down-regulated rapidly at a post-transcriptional level in cells deprived of the nitrogen source. In addition to the fact that Cln3 is degraded faster by ubiquitin-dependent mechanisms, we have found that translation of the CLN3 mRNA is repressed approximately 8-fold under nitrogen deprivation conditions. As a consequence, both SBF- and MBF-dependent expression is strongly down-regulated. Mainly because of their transcriptional dependence on SBF, and perhaps with the contribution of similar post-transcriptional mechanisms to those found for Cln3, the G1 cyclins Cln1 and 2 become undetectable in starved cells. The complete loss of Cln cyclins and the sustained presence of the Clb-cyclin kinase inhibitor Sic1 in starved cells may provide the molecular basis for the G1 arrest caused by nitrogen deprivation. Show less
no PDF DOI: 10.1093/emboj/16.23.7196
CLN3
I Järvelä, T Autti, S Lamminranta +3 more · 1997 · Annals of neurology · Wiley · added 2026-04-24
A total of 36 patients with Batten disease (juvenile-onset neuronal ceroid lipofuscinosis), homozygous or heterozygous for the major mutation, a 1.02-kb deletion, in the CLN3 gene, were studied to rel Show more
A total of 36 patients with Batten disease (juvenile-onset neuronal ceroid lipofuscinosis), homozygous or heterozygous for the major mutation, a 1.02-kb deletion, in the CLN3 gene, were studied to relate their genotype to their clinical phenotype. The onset of visual failure and epilepsy was highly concordant in both groups. Great inter- and intrafamilial heterogeneity was demonstrated in the development of mental and physical handicap and in magnetic resonance imaging findings among both homozygous and heterozygous patients. The 1.02-kb deletion in homozygous form was always associated with mental and physical handicap, whereas the heterozygous phenotype could be extremely benign without affecting the intellectual level of the patient. Our data suggest that genetic background, modifying genes, and environmental factors all influence the final phenotype of Batten disease. Show less
no PDF DOI: 10.1002/ana.410420517
CLN3
P E Taschner, N de Vos, M H Breuning · 1997 · Journal of medical genetics · added 2026-04-24
The recent isolation of the CLN3 gene involved in Batten disease (juvenile neuronal ceroid lipofuscinosis) creates possibilities for direct detection of mutations which can confirm or indicate the cli Show more
The recent isolation of the CLN3 gene involved in Batten disease (juvenile neuronal ceroid lipofuscinosis) creates possibilities for direct detection of mutations which can confirm or indicate the clinical diagnosis of Batten disease. We have designed a rapid and reliable allele specific PCR test for the detection of the major deletion, which can be used in carrier diagnosis, presymptomatic diagnosis, and prenatal diagnosis. Show less
no PDF DOI: 10.1136/jmg.34.11.955
CLN3
H H Silljé, E G ter Schure, A J Rommens +5 more · 1997 · Journal of bacteriology · added 2026-04-24
By controlled addition of galactose to synchronized galactose-limited Saccharomyces cerevisiae cultures, the growth rate could be regulated while external conditions were kept constant. By using this Show more
By controlled addition of galactose to synchronized galactose-limited Saccharomyces cerevisiae cultures, the growth rate could be regulated while external conditions were kept constant. By using this method, the G1 phase duration was modulated and expression of cell cycle-regulated genes was investigated. The expression of the cyclin genes CLN1 and CLN2 was always induced just before bud emergence, indicating that this event marks the decision to pass Start. Thus, G1 phase elongation was not due to a slower accumulation of the CLN1 and CLN2 mRNA levels. Only small differences in CLN3 expression levels were observed. The maximal SWI4 expression preceded maximal CLN1 and CLN2 expression under all conditions, as expected for a transcriptional activator. But whereas SWI4 was expressed at about 10 to 20 min, before CLN1 and CLN2 expression at high growth rates, this time increased to about 300 min below a particular consumption rate at which the G1 phase strongly elongated. In the slower-growing cultures, also an increase in SWI6 expression was observed in the G1 phase. The increase in G1 phase duration below a particular consumption rate was accompanied by a strong increase in the reserve carbohydrate levels. These carbohydrates were metabolized again before bud emergence, indicating that below this consumption rate, a transient increase in ATP flux is required for progression through the cell cycle. Since Start occurred at different cell sizes under different growth conditions, it is not just a certain cell size that triggers passage through Start. Show less
no PDF DOI: 10.1128/jb.179.21.6560-6565.1997
CLN3
M L Katz, C L Gao, M Prabhakaram +3 more · 1997 · Investigative ophthalmology & visual science · added 2026-04-24
Batten disease, also known as juvenile ceroid-lipofuscinosis and CLN3, is an autosomal recessively inherited disorder that results in blindness due to retinal degeneration. The CLN3 gene has been iden Show more
Batten disease, also known as juvenile ceroid-lipofuscinosis and CLN3, is an autosomal recessively inherited disorder that results in blindness due to retinal degeneration. The CLN3 gene has been identified, but the function of the protein that this gene encodes is unknown. Experiments were conducted to determine where the CLN3 protein is localized in the mouse retina. Localization should provide a clue in evaluating potential functions of this protein. Using oligonucleotide primers based on the reported human CLN3 cDNA sequence, the mouse cDNA nucleotide sequence was determined from products of the reverse transcriptase-polymerase chain reaction and 3' rapid amplification of cDNA ends. A synthetic 20-amino-acid peptide corresponding to an internal hydrophilic region of the predicted amino acid sequence of the mouse CLN3 protein was used to immunize rabbits. The resulting antiserum was used in immunoblot analysis of mouse retina homogenates and in electron microscopic immunocytochemical labeling of mouse retina sections. The peptide antibody labeled a single protein band of approximately 50 kDa on immunoblots of mouse retina homogenates. No labeling was detected with homogenates from human retinas. The antibody specifically labeled mitochondria of Müller cells and inner retinal neurons. Little labeling was observed in mitochondria of the photoreceptor cells. Mitochondria of other cell types, including the retinal pigment epithelium and choroidal cells, were not labeled. The retinal CLN3 protein appears to be localized almost exclusively in the mitochondria, but was detected only in certain cell types. Batten disease is characterized by massive lysosomal accumulations of a small inner mitochondrial membrane protein (subunit c of ATP synthase). The mitochondrial localization of the CLN3 protein suggests that it may play a role in the normal processing of subunit c. Show less
no PDF
CLN3
K N Huang, S A Odinsky, F R Cross · 1997 · Molecular and cellular biology · added 2026-04-24
We have generated 50 new alleles of the yeast CLN2 gene by using site-directed mutagenesis. With the recently obtained crystal structure of cyclin A as a guide, a peptide linker sequence was inserted Show more
We have generated 50 new alleles of the yeast CLN2 gene by using site-directed mutagenesis. With the recently obtained crystal structure of cyclin A as a guide, a peptide linker sequence was inserted at 13 sites within the cyclin box of Cln2 to determine if the architecture of Cln2 is similar to that of cyclin A. Linkers inserted in what are predicted to be helices 1, 2, 3, and 5 of the cyclin box resulted in nonfunctional Cln2 molecules. Linkers inserted between these putative helix sites and in the region believed to contain a fourth helix did not have significant effects upon Cln2 function. A series of deletions in the region between the third and fifth helices indicate that the putative fourth helix may lie at the C-terminal end of this region yet is not essential for function. Two residues that are predicted to form a buried salt bridge important for interaction of two helices of the cyclin box were also mutated, and an additional set of 31 mutant alleles was generated by clustered-charge-to-alanine scanning mutagenesis. All of the mutant CLN2 alleles made in this study were tested in a variety of genetic and functional assays previously demonstrated to differentiate specific cyclin functions. Some alleles demonstrated restricted patterns of defects, suggesting that these mutations may interfere with specific aspects of Cln2 function. Show less
no PDF DOI: 10.1128/MCB.17.8.4654
CLN3
P Radcliffe, J Trevethick, M Tyers +1 more · 1997 · Yeast (Chichester, England) · Wiley · added 2026-04-24
Wild-type cells of the budding yeast Saccharbmyces cerevisiae arrest in G1 upon nutrient exhaustion. Cell cycle arrest requires the WHI2 gene since whi2 mutants continue to divide and become abnormall Show more
Wild-type cells of the budding yeast Saccharbmyces cerevisiae arrest in G1 upon nutrient exhaustion. Cell cycle arrest requires the WHI2 gene since whi2 mutants continue to divide and become abnormally small as nutrients are depleted. Here we show that CLN1 and CLN2 transcript levels in a whi2 strain are higher during exponential growth, and persist longer upon starvation, than in an isogenic wild-type strain. In contrast to CLN1 and CLN2, CLN3 levels declined only at very high cell density and were unaffected by the whi2 mutation. Elevated CLN expression is sufficient to explain the whi2 phenotype since ectopic expression of CLN1 in a nutrient-depleted culture caused cells to continue dividing and interfered with the acquisition of heat resistance. These observations show that, either directly or indirectly, Whi2 negatively regulates G1 cyclin expression. Interestingly extremely high levels of Cln1 induced filamentous growth upon nutrient deprivation, suggesting a direct connection between G1 cyclin activity and morphological responses to poor nutrient conditions. Show less
no PDF DOI: 10.1002/(SICI)1097-0061(19970630)13:8<707::AID-YEA130>3.0.CO;2-9
CLN3
D A Pearce, F Sherman · 1997 · Yeast (Chichester, England) · Wiley · added 2026-04-24
The Saccharomyces cerevisiae gene BTN1, encodes a 408 amino acid putative integral membrane protein, which is 39% identical and 59% similar to the human Cln3p, whose mutant forms are responsible for B Show more
The Saccharomyces cerevisiae gene BTN1, encodes a 408 amino acid putative integral membrane protein, which is 39% identical and 59% similar to the human Cln3p, whose mutant forms are responsible for Batten's disease and for a diminished degradation of mitochondrial ATPase synthase subunit c. Disruption experiments established that Btn1p is not essential for viability, mitochondrial function, or degradation of mitochondrial ATP synthase in yeast. Show less
no PDF DOI: 10.1002/(SICI)1097-0061(19970630)13:8<691::AID-YEA123>3.0.CO;2-D
CLN3
T Chen, J Kurjan · 1997 · Molecular and cellular biology · added 2026-04-24
SST2 plays an important role in the sensitivity of yeast cells to pheromone and in recovery from pheromone-induced G1 arrest. Recently, a family of Sst2p homologs that act as GTPase-activating protein Show more
SST2 plays an important role in the sensitivity of yeast cells to pheromone and in recovery from pheromone-induced G1 arrest. Recently, a family of Sst2p homologs that act as GTPase-activating proteins (GAPs) for G alpha subunits has been identified. We have identified an interaction between Sst2p and the previously identified Mpt5p by using the two-hybrid system. Loss of Mpt5p function resulted in a temperature-sensitive growth phenotype, an increase in pheromone sensitivity, and a defect in recovery from pheromone-induced G1 arrest, although the effects on pheromone response and recovery were mild in comparison to those of sst2 mutants. Overexpression of either Sst2p or Mpt5p promoted recovery from G1 arrest. Promotion of recovery by overexpression of Mpt5p required Sst2p, but the effect of overexpression of Sst2p was only partially dependent on Mpt5p. Mpt5p was also found to interact with the mitogen-activated protein kinase homologs Fus3p and Kss1p, and an mpt5 mutation was able to suppress the pheromone arrest and mating defects of a fus3 mutant. Because either mpt5 or cln3 mutations suppressed the fus3 phenotypes, interactions of Mpt5p with the G1 cyclins and Cdc28p were tested. An interaction between Mpt5p and Cdc28p was detected. We discuss these results with respect to a model in which Sst2p plays a role in pheromone sensitivity and recovery that acts through Mpt5p in addition to a role as a G alpha GAP suggested by the analysis of the Sst2p homologs. Show less
no PDF DOI: 10.1128/MCB.17.6.3429
CLN3
A Amon · 1997 · The EMBO journal · Oxford University Press · added 2026-04-24
In budding yeast, stability of the mitotic B-type cyclin Clb2 is tightly cell cycle-regulated. B-type cyclin proteolysis is initiated during anaphase and persists throughout the G1 phase. Cln-Cdc28 ki Show more
In budding yeast, stability of the mitotic B-type cyclin Clb2 is tightly cell cycle-regulated. B-type cyclin proteolysis is initiated during anaphase and persists throughout the G1 phase. Cln-Cdc28 kinase activity at START is required to repress B-type cyclin-specific proteolysis. Here, we show that Clb-dependent kinases, when expressed during G1, are also capable of repressing the B-type cyclin proteolysis machinery. Furthermore, we find that inactivation of Cln- and Clb-Cdc28 kinases is sufficient to trigger Clb2 proteolysis and sister-chromatid separation in G2/M phase-arrested cells, where the B-type cyclin-specific proteolysis machinery is normally inactive. Our results suggest that Cln- and Clb-dependent kinases are both capable of repressing B-type cyclin-specific proteolysis and that they are required to maintain the proteolysis machinery in an inactive state in S and G2/M phase-arrested cells. We propose that in yeast, as cells pass through START, Cln-Cdc28-dependent kinases inactivate B-type cyclin proteolysis. As Cln-Cdc28-dependent kinases decline during G2, Clb-Cdc28-dependent kinases take over this role, ensuring that B-type cyclin proteolysis is not activated during S phase and early mitosis. Show less
no PDF DOI: 10.1093/emboj/16.10.2693
CLN3
C J McInerny, J F Partridge, G E Mikesell +2 more · 1997 · Genes & development · Cold Spring Harbor Laboratory · added 2026-04-24
We have identified a novel promoter element that confers M/G1-specific transcription in Saccharomyces cerevisiae. This element, which we call an ECB (early cell cycle box), was first identified in the Show more
We have identified a novel promoter element that confers M/G1-specific transcription in Saccharomyces cerevisiae. This element, which we call an ECB (early cell cycle box), was first identified in the SWI4 promoter, but it is also present in the promoter of a G1 cyclin CLN3, as well as in the promoters of three DNA replication genes: CDC6, CDC47, and CDC46. Transcripts from all five of these genes oscillate during the cell cycle and peak at the M/G1 boundary, as do isolated ECB elements in reporter constructs. The ECB element contains an Mcm1 binding site to which Mcm1 binds in vitro, and an Mcm1-VP16 fusion, which places a constitutive activator on Mcm1-binding sites in vivo, can deregulate ECB-containing promoters. Mcm1 is a transcription factor that is also required for minichromosome maintenance. We provide evidence that the replication defect of mcm1 mutants can be suppressed by ectopic CDC6 transcription. Periodic expression of SWI4 and CLN3 may be important for cell cycle progression, as we find that these genes are both haploinsufficient and rate limiting for G1 progression. We suggest that ECB-regulated gene products play critical roles in promoting the initiation of S-phase, both by regulating CLN1 and CLN2 transcription and as components of the initiation complex on origins of replication. Show less
no PDF DOI: 10.1101/gad.11.10.1277
CLN3
M S Santisteban, G Arents, E N Moudrianakis +1 more · 1997 · The EMBO journal · Oxford University Press · added 2026-04-24
Within the core histone octamer each histone H4 interacts with each H2A-H2B dimer subunit through two binding surfaces. Tyrosines play a central role in these interactions with H4 tyrosines 72 and 88 Show more
Within the core histone octamer each histone H4 interacts with each H2A-H2B dimer subunit through two binding surfaces. Tyrosines play a central role in these interactions with H4 tyrosines 72 and 88 contacting one H2A-H2B dimer subunit, and tyrosine 98 contacting the other. To investigate the roles of these interactions in vivo, we made site-directed amino acid substitutions at each of these tyrosine residues. Elimination of either set of interactions is lethal, suggesting that binding of the tetramer to both dimers is essential. Temperature-sensitive mutants were obtained through single amino acid substitutions at each of the tyrosines. The mutants show both strong positive and negative effects on transcription. Positive effects include Spt- and Sin-phenotypes resulting from mutations at each of the three tyrosines. One allele has a strong negative effect on the expression of genes essential for the G1 cell cycle transition. At restrictive temperature, mutant cells fail to express the CLN1, CLN2, SWI4 and SWI6 genes, and have reduced levels of CLN3 mRNA. These results demonstrate the critical role of histone dimer-tetramer interactions in vivo, and define their essential role in the expression of genes regulating G1 cell cycle progression. Show less
no PDF DOI: 10.1093/emboj/16.9.2493
CLN3
J D Sharp, R B Wheeler, B D Lake +5 more · 1997 · Human molecular genetics · Oxford University Press · added 2026-04-24
The childhood neuronal ceroid lipofuscinoses (NCLs) are a group of autosomal recessive neurodegenerative disorders characterised by progressive visual failure, neurodegeneration, epilepsy and the accu Show more
The childhood neuronal ceroid lipofuscinoses (NCLs) are a group of autosomal recessive neurodegenerative disorders characterised by progressive visual failure, neurodegeneration, epilepsy and the accumulation of an autofluorescent lipopigment in neurones and other cells. Three main subtypes have been identified according to age of onset, clinical features and ultrastructural morphology. These are infantile NCL (INCL; CLN1), classical late infantile NCL (LINCL; CLN2) and juvenile NCL (JNCL; CLN3). Several atypical forms of late infantile NCL (LINCL) have also been described including a Finnish variant LINCL (CLN5). The CLN2 gene has been excluded from the CLN1, CLN3 and CLN5 loci. A genome search was initiated using a homozygosity mapping strategy in five classical LINCL and two variant LINCL consanguineous families. A common region of homozygosity was identified on chromosome 11p15 in two of the classical families. Analysis of a further 33 classical LINCL families supported linkage in this region (Zmax = 3.07 at theta = 0.06 at D11S1338). A common region of homozygosity was also observed on chromosome 15q21-23 in the two variant LINCL families. Extension of the analysis to include a further seven families of identical ultrastructural phenotype established linkage to this region (Zmax = 6.00 at theta = 0.00 at D15S1020). Show less
no PDF DOI: 10.1093/hmg/6.4.591
CLN3
H M Mitchison, P B Munroe, A M O'Rawe +14 more · 1997 · Genomics · added 2026-04-24
We recently cloned a cDNA for CLN3, the gene for juvenile-onset neuronal ceroid lipofuscinosis or Batten disease. To resolve the genomic organization we used a cosmid clone containing CLN3 to sequence Show more
We recently cloned a cDNA for CLN3, the gene for juvenile-onset neuronal ceroid lipofuscinosis or Batten disease. To resolve the genomic organization we used a cosmid clone containing CLN3 to sequence the entire gene in addition to 1.1 kb 5' of the start of the published CLN3 cDNA and 0.3 kb 3' to the polyadenylation site. CLN3 is organized into at least 15 exons spanning 15 kb and ranging from 47 to 356 bp. The 14 introns vary from 80 to 4227 bp, and all exon/intron junction sequences conform to the GT/AG rule. Numerous repetitive Alu elements are present within the introns and 5'- and 3'-untranslated regions. The 5' region of the CLN3 gene contains several potential transcription regulatory elements but no consensus TATA-1 box was identified. CLN3 is homologous to 27 deposited human ESTs, and sequence comparisons suggest alternative splicing of the gene and the existence of transcribed sequences upstream to the start of the published CLN3 cDNA. Show less
no PDF DOI: 10.1006/geno.1996.4576
CLN3
V Measday, L Moore, R Retnakaran +4 more · 1997 · Molecular and cellular biology · added 2026-04-24
In budding yeast, entry into the mitotic cell cycle, or Start, requires the Cdc28 cyclin-dependent kinase (Cdk) and one of its three associated G1 cyclins, Cln1, Cln2, or Cln3. In addition, two other Show more
In budding yeast, entry into the mitotic cell cycle, or Start, requires the Cdc28 cyclin-dependent kinase (Cdk) and one of its three associated G1 cyclins, Cln1, Cln2, or Cln3. In addition, two other G1 cyclins, Pcl1 and Pcl2, associate with a second Cdk, Pho85, to contribute to Start. Although Pho85 is not essential for viability, Pcl1,2-Pho85 kinase complexes become essential for Start in the absence of Cln1,2-Cdc28 kinases. In addition, Pho85 interacts with a third cyclin, Pho80, to regulate acid phosphatase gene expression. Other cellular roles for Pho85 cyclin-Cdk complexes are suggested by the multiple phenotypes associated with deletion of PHO85, in addition to Start defects and deregulated acid phosphatase gene expression. Strains with pho80, pcl1, and pcl2 deletions show only a subset of the pho85 mutant phenotypes, suggesting the existence of additional Pho85 cyclins (Pcls). We used two-hybrid screening and database searching to identify seven additional cyclin-related genes that may interact with Pho85. We found that all of the new genes encode proteins that interacted with Pho85 in an affinity chromatography assay. One of these genes, CLG1, was previously suggested to encode a cyclin, based on the protein's sequence homology to Pcl1 and Pcl2. We have named the other genes PCL5, PCL6, PCL7, PCL8, PCL9, and PCL10. On the basis of sequence similarities, the PCLs can be divided into two subfamilies: the Pcl1,2-like subfamily and the Pho80-like subfamily. We found that deletion of members of the Pcl1,2 class of genes resulted in pronounced morphological abnormalities. In addition, we found that expression of one member of the Pcl1,2 subfamily, PCL9, is cell cycle regulated and is decreased in cells arrested in G1 by pheromone treatment. Our studies suggest that Pho85 associates with multiple cyclins and that subsets of cyclins may direct Pho85 to perform distinct roles in cell growth and division. Show less
no PDF DOI: 10.1128/MCB.17.3.1212
CLN3
M J Bennett, R L Boriack, D G Birch · 1997 · Neuropediatrics · added 2026-04-24
We have studied the effects of polyunsaturated fatty acid (PUFA) supplementation in utero and throughout life in mnd mutant mice, a proposed model for juvenile neuronal ceroid lipofuscinosis (CLN-3). Show more
We have studied the effects of polyunsaturated fatty acid (PUFA) supplementation in utero and throughout life in mnd mutant mice, a proposed model for juvenile neuronal ceroid lipofuscinosis (CLN-3). Unlike our earlier in-vitro studies in humans with CLN-3, and in-vitro studies in CLN-3 lymphoblasts, we saw no beneficial effects in electroretinographic, electron microscopic or clinical studies in the mnd mice. Electron microscopy of brain revealed a pattern which was not consistent with the characteristic ceroid patterns in CLN-3. Our data suggest that the mnd mouse is not responsive to PUFA supplementation and may not be an appropriate animal model for CLN-3. Show less
no PDF DOI: 10.1055/s-2007-973678
CLN3
M Philippart, E da Silva, H T Chugani · 1997 · Neuropediatrics · added 2026-04-24
Positron Emission Tomography (PET) with 2-deoxy-2 [18F]-fluoro-D-glucose provides a measure of functional brain activity, particularly in the dendritic field. In CLN3 (juvenile neuronal ceroid lipofus Show more
Positron Emission Tomography (PET) with 2-deoxy-2 [18F]-fluoro-D-glucose provides a measure of functional brain activity, particularly in the dendritic field. In CLN3 (juvenile neuronal ceroid lipofuscinosis or juvenile Batten disease, with fingerprint inclusions) hypometabolism slowly spreads from calcarine to anterior areas, sparing subcortical structures and brainstem. In CLN2 (late infantile neuronal ceroid lipofuscinosis or Jansky-Bielschowsky disease, with curvilinear inclusions) degeneration is rapid with generalized cortical and subcortical hypometabolism. This is associated with rapidly progressive cerebral atrophy on anatomical neuroimaging. A 4-year-old child with CLN2 scanned with PET 13 months after the clinical onset showed hypometabolism, severe in the thalamus and mild in cortical areas. Three other patients with CLN2 had severe generalized hypometabolism and brain atrophy. Longitudinal PET studies in CLN may provide key insights into degenerative processes. Show less
no PDF DOI: 10.1055/s-2007-973675
CLN3
A C Syvänen, I Järvelä, T Paunio +1 more · 1997 · Neuropediatrics · added 2026-04-24
The recent identification of the genes and the mutations underlying infantile neuronal ceroid lipofuscinosis and juvenile onset neuronal ceroid lipofuscinosis facilitates specific DNA-based diagnostic Show more
The recent identification of the genes and the mutations underlying infantile neuronal ceroid lipofuscinosis and juvenile onset neuronal ceroid lipofuscinosis facilitates specific DNA-based diagnostics for the disorders. We have developed a solid-phase minisequencing test for the identification of the major Finnish INCL mutation, an A to T transversion at nucleotide position 364 of the palmitoyl protein thioesterase gene on chromosome 1. This test has been applied for prenatal diagnosis and for identification of disease carriers in INCL families. For population-based screening for INCL carriers the coverage of the test would be 98%. In addition, by combining the solid-phase minisequencing test with whole genome preamplification, we have developed a procedure that allows reliable identification of the INCLFin-mutation in single blastomeres from in-vitro-fertilized embryos. This method is applicable for preimplantation diagnosis, and thus it offers an alternative to early prenatal diagnosis in the prevention of INCL. A modification of the solid-phase minisequencing test was devised for detection of the major INCL mutation, a 1.02 kb deletion in the CLN3 gene on chromosome 16. The coverage of this test for diagnosis of INCL and identification of carriers is 90% in Finland and > 80% worldwide. Show less
no PDF DOI: 10.1055/s-2007-973671
CLN3
R K Pullarkat, G N Morris · 1997 · Neuropediatrics · added 2026-04-24
The carboxyl terminal of the predicted amino acid sequence of the Batten disease CLN3 gene protein is CQLS. This motif is expected to be a site for farnesylation at the cysteine residue. In order to d Show more
The carboxyl terminal of the predicted amino acid sequence of the Batten disease CLN3 gene protein is CQLS. This motif is expected to be a site for farnesylation at the cysteine residue. In order to determine whether this is indeed farnesylated we have carried out the in-vitro prenylation of tetrapeptides CVLS, CAIL and CQLS using a farnesyl transferase preparation from bovine brain. The data shows that the CQLS is a good acceptor of a farnesyl group similar to CVLS while it is a poor acceptor of a geranylgeranyl group unlike CAIL, which is a good acceptor of a geranylgeranyl group. This suggests that the CLN3 gene product may be a farnesylated protein. Show less
no PDF DOI: 10.1055/s-2007-973665
CLN3
K Puranam, W H Qian, K Nikbakht +4 more · 1997 · Neuropediatrics · added 2026-04-24
The late infantile and juvenile variants of Batten disease are genetically distinct neurodegenerative disorders. Hallmarks of Batten disease include cognitive and motor decline, seizures and blindness Show more
The late infantile and juvenile variants of Batten disease are genetically distinct neurodegenerative disorders. Hallmarks of Batten disease include cognitive and motor decline, seizures and blindness due to retinitis pigmentosa. Recently, the CLN3 gene responsible for the juvenile variant has been cloned. Also, apoptosis was proven to be the mechanism by which neurons and photoreceptors die. This paper provides mechanistic support for the occurrence of apoptosis in this disease: There was marked upregulation of Bcl-2 in brain from the late infantile and juvenile types at the protein and RNA levels both by immunocytochemistry and by Northern blot analysis; there were also a 42% to 197% increase in brain ceramide determinations in brains from three patients with the juvenile type and three patients with the late infantile type. Double immunolabeling of brain sections for apoptosis and Bcl-2 supported a protective role for Bcl-2 in the juvenile form of Batten disease. These results raise the possibility that the intact CLN3 gene is normally antiapoptotic, and that it could be an upstream regulator of ceramide. Show less
no PDF DOI: 10.1055/s-2007-973664
CLN3
M Elleder, J Franc, J Kraus +3 more · 1997 · European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society · Elsevier · added 2026-04-24
A series of 57 patients (from 51 families) with neuronal ceroid lipofuscinosis (NCL) has been diagnosed during the last 25 years. Using clinical and electrophysiological criteria together with results Show more
A series of 57 patients (from 51 families) with neuronal ceroid lipofuscinosis (NCL) has been diagnosed during the last 25 years. Using clinical and electrophysiological criteria together with results of ultrastructural, histochemical, immunohistochemical and neuropathological analyses it has been possible to classify the following NCL types. Two cases were of the infantile type (CLN1), one case of the juvenile (CLN3) type and one case of the adult (CLN4) type. The bulk of the series was represented by 26 cases of the late infantile (CLN2) type and by 27 cases of the early juvenile (CLN6) type (also called non-Finnish variant late infantile, or Lake-Cavanagh). Besides the infantile form, microcephaly was a relatively frequent finding (nine cases) in the late infantile and early juvenile NCLs. In more than half of the late infantile and early juvenile cases there was a significant reduction of the nerve conduction velocity. The early juvenile CLN6 type was found to have a relatively high incidence in the Romany population (12 cases in nine families). Incidence of NCL in the Czech republic is estimated to be 1.3:100,000. Show less
no PDF DOI: 10.1016/s1090-3798(97)80041-4
CLN3
K E Wiśniewski, N Zhong, E Kida +5 more · 1997 · Folia neuropathologica · added 2026-04-24
We have collected 122 late-infantile neuronal ceroid lipofuscinosis (LINCL, CLN2) and 191 juvenile NCL (JNCL, CLN3) cases, diagnosed on the basis of age-at-onset, clinical symptomatology, and patholog Show more
We have collected 122 late-infantile neuronal ceroid lipofuscinosis (LINCL, CLN2) and 191 juvenile NCL (JNCL, CLN3) cases, diagnosed on the basis of age-at-onset, clinical symptomatology, and pathological findings and representing the most common forms of NCL in the United States, and Europe. However, careful analysis of available data revealed that about 80% of cases show typical and 20% show atypical clinical course and/or pathological findings and thus, may represent variants of LINCL and JNCL, respectively. Recent progress in the biochemistry and molecular genetics of NCL inclined us to reevaluate these atypical NCL cases. The gene responsible for LINCL has not yet been identified, except for the Finnish variant. Accumulation of subunit c of mitochondrial ATP synthase, to curvilinear profiles, is found in LINCL cases. A novel variant of LINCL, with predominantly granular profiles in the lysosomal storage, as well as normal excretion of subunit c in urine samples, was found in five cases. When the palmitoyle-protein thioesterase (PPT) was studied in these five cases, it was found that the level was deficient, suggesting that they are not LINCL, but the infantile form of neuronal ceroid lipofuscinosis (INCL). Using molecular genetic techniques in the typical JNCL cases, common 1.02 kb deletion to CLN3 was found in 23/27 (homozygotes) and in one allele 4/27 (heterozygotes) in affected pedigrees. In atypical JNCL pedigrees, it was found in 5/16 heterozygotes, while in 1/5 pedigrees, a novel mutation of one atypical JNCL where a single amino acid substitution at 295 E-->K was found in one allele. None of the atypical JNCL cases was homozygote. In atypical JNCL cases where mutation in CLN3 has not been identified (11/16 probands), several possibilities may exist. The phenotype may be caused by a yet undefined mutation in CLN3 or may be due to phenotypically overlapping with other forms of NCL. Pheno/genotypic correlation and the diagnostic difficulties are discussed. Show less
no PDF
CLN3
B L Schneider, Q H Yang, A B Futcher · 1996 · Science (New York, N.Y.) · Science · added 2026-04-24
In Saccharomyces cerevisiae, three G1 cyclins (Clns) are important for Start, the event committing cells to division. Sic1, an inhibitor of C1b-Cdc28 kinases, became phosphorylated at Start, and this Show more
In Saccharomyces cerevisiae, three G1 cyclins (Clns) are important for Start, the event committing cells to division. Sic1, an inhibitor of C1b-Cdc28 kinases, became phosphorylated at Start, and this phosphorylation depended on the activity of Clns. Sic1 was subsequently lost, which depended on the activity of Clns and the ubiquitin-conjugating enzyme Cdc34. Inactivation of Sic1 was the only nonredundant essential function of Clns, because a sic1 deletion rescued the inviability of the cln1 cln2 cln3 triple mutant. In sic1 mutants, DNA replication became uncoupled from budding. Thus, Sic1 may be a substrate of Cln-Cdc28 complexes, and phosphorylation and proteolysis of Sic1 may regulate commitment to replication at Start. Show less
no PDF DOI: 10.1126/science.272.5261.560
CLN3
C Koch, A Schleiffer, G Ammerer +1 more · 1996 · Genes & development · Cold Spring Harbor Laboratory · added 2026-04-24
When yeast cells reach a critical size in late G1 they simultaneously start budding, initiate DNA synthesis, and activate transcription of a set of genes that includes G1 cyclins CLN1, CLN2, and many Show more
When yeast cells reach a critical size in late G1 they simultaneously start budding, initiate DNA synthesis, and activate transcription of a set of genes that includes G1 cyclins CLN1, CLN2, and many DNA synthesis genes. Cell cycle-regulated expression of CLN1, CLN2 genes is attributable to the heteromeric transcription factor complex SBF. SBF is composed of Swi4 and Swi6 and binds to the promoters of CLN1 and CLN2. Different cyclin-Cdc28 complexes have different effects on late G1-specific transcription. Activation of transcription at the G1/S boundary requires Cdc28 and one of the G1 cyclins Cln1-Cln3, whereas repression of SBF-regulated genes in G2 requires the association of Cdc28 with G2-specific cyclins Clb1-Clb4. Using in vivo genomic footprinting, we show that SBF (Swi4/Swi6) binding to SCB elements (Swi4/Swi6 cell cycle box) in the CLN2 promoter is cell cycle regulated. SBF binds to the promoter prior to the activation of transcription in late G1, suggesting that Cln/Cdc28 kinase regulates the ability of previously bound SBF to activate transcription. In contrast, SBF dissociates from the CLN2 promoter when transcription is repressed during G2 and M phases, suggesting that Clb1-Clb4 repress SBF activity by inhibiting its DNA-binding activity. Switching transcription on and off by different mechanisms could be important to ensure that Clns are activated only once per cell cycle and could be a conserved feature of cell cycle-regulated transcription. Show less
no PDF DOI: 10.1101/gad.10.2.129
CLN3
B K Benton, S D Plump, J Roos +2 more · 1996 · Current genetics · added 2026-04-24
In budding yeast, one of three G1 cyclins is required for progression though START, when cells commit to a further round of cell division. We have identified mutations in ALG1 (ERC14), a gene required Show more
In budding yeast, one of three G1 cyclins is required for progression though START, when cells commit to a further round of cell division. We have identified mutations in ALG1 (ERC14), a gene required for N-glycosylation, which are inviable in a cln1 cln2 background but are rescued by over-expression of CLNs. CLN1 and CLN2 are much more efficient than CLN3 in rescuing the erc14-1 allele. The erc14-1 allele results in a significant N-glycosylation defect, and no rescue of this defect by CLN1 over-expression was detected. These data suggest that CLN over-expression could be allowing cells to live with lower levels of N-glycosylation, possibly by overcoming a checkpoint sensitive to N-glycosylation capacity. A plasmid suppressor of alg1, PSA1, encodes a 361 amino-acid protein with homology to NDP-hexose pyrophosphorylases, the enzymes that catalyze the formation of activated sugar nucleotides. PSA1 is an essential gene, and PSA1 transcription is nearly co-ordinately regulated with CLN2 transcription, peaking near START. Co-ordinate regulation of glycosylation, sugar nucleotide metabolism, and cell-cycle progression through G1 may be a feature that ensures adequate cell-wall precursors are present before bud emergence. Show less
no PDF
CLN3
S E Mole · 1996 · Journal of inherited metabolic disease · Springer · added 2026-04-24
Major advances in the molecular genetic analysis of the neuronal ceroid lipofuscinoses (NCL) have recently been made: the genes for two major types have been identified and the chromosomal location fo Show more
Major advances in the molecular genetic analysis of the neuronal ceroid lipofuscinoses (NCL) have recently been made: the genes for two major types have been identified and the chromosomal location for a third defined. CLN1, the gene for infantile NCL (Santavuori-Haltia disease) encodes palmitoyl protein thioesterase (PPT). Most patients (75% of disease chromosomes) have the same point mutation. In contrast, CLN3, the gene for juvenile NCL (Batten or Spielmeyer-Vogt-Sjögren disease) is not a previously known gene, nor does its product display homology to any previously described proteins. The same 1 kb genomic deletion is present in the majority of patients (81% of disease chromosomes). CLN5, the gene for Finnish variant late infantile NCL, has been mapped to 13q and should be identified in the near future. The gene for late-infantile NCL (Jansky-Bielschowsky disease) has not yet been localized to a chromosome despite intensive research. It is likely that this type of NCL is caused by mutations in more than one gene each resulting in the same phenotype. Show less
no PDF DOI: 10.1007/BF01799253
CLN3
N C Barbet, U Schneider, S B Helliwell +3 more · 1996 · Molecular biology of the cell · American Society for Cell Biology · added 2026-04-24
Saccharomyces cerevisiae cells treated with the immunosuppressant rapamycin or depleted for the targets of rapamycin TOR1 and TOR2 arrest growth in the early G1 phase of the cell cycle. Loss of TOR fu Show more
Saccharomyces cerevisiae cells treated with the immunosuppressant rapamycin or depleted for the targets of rapamycin TOR1 and TOR2 arrest growth in the early G1 phase of the cell cycle. Loss of TOR function also causes an early inhibition of translation initiation and induces several other physiological changes characteristic of starved cells entering stationary phase (G0). A G1 cyclin mRNA whose translational control is altered by substitution of the UBI4 5' leader region (UBI4 is normally translated under starvation conditions) suppresses the rapamycin-induced G1 arrest and confers starvation sensitivity. These results suggest that the block in translation initiation is a direct consequence of loss of TOR function and the cause of the G1 arrest. We propose that the TORs, two related phosphatidylinositol kinase homologues, are part of a novel signaling pathway that activates eIF-4E-dependent protein synthesis and, thereby, G1 progression in response to nutrient availability. Such a pathway may constitute a checkpoint that prevents early G1 progression and growth in the absence of nutrients. Show less
no PDF DOI: 10.1091/mbc.7.1.25
CLN3